Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

ClinicalTrials.gov Identifier: NCT04935359

Novartis Reference Number: CNIS793B12301

Last Update: Jan 30, 2023

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

This study aims to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel can reduce fibrosis in PDAC, restore chemo-sensitivity and ultimately lead to improvements in overall survival (OS) and other clinically relevant outcomes.

Condition 
Metastatic Pancreatic Ductal Adenocarcinoma
Phase 
Phase 3
Overall status 
Recruiting
Start date 
Sep 30, 2021
Completion date 
Jan 01, 2026
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Drug
NIS793
Concentrate for solution infusion (Liquid in Vial)
Drug
Nab-paclitaxel
Per locally approved formulation
Drug
Gemcitabine
Per locally approved formulation
Drug
Placebo
Dextrose 5% in water (D5W) solution for infusion

Eligibility Criteria

Inclusion Criteria:

Applicable for both Safety run-in and Randomized part

Participants aged ≥18 years with histologically or cytologically confirmed (based on local assessment and per local guidelines) mPDAC eligible for treatment in the first line setting and not amenable for potentially curative surgery
Presence of at least one measurable lesion assessed by Computerized Tomography (CT) and/or Magnetic Resonance Imaging (MRI) according to RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Adequate organ function (assessed by central laboratory for eligibility)
Participants must have recovered from treatment-related toxicities of prior anticancer therapies to grade ≤ 1 (CTCAE v 5.0) at time of screening, except alopecia.

Main Exclusion Criteria:

Applicable for both Safety run-in and Randomized part

Previous systemic anti-cancer treatment for metastatic PDAC
Pancreatic neuroendocrine, acinar, or islet tumors
Participants with known status of microsatellite instability-high (MSI-H) or mismatch repair-deficient pancreatic cancer (if status is not already available, testing is not required at screening).
Participant has not recovered from a major surgery performed prior to start of study treatment or has had a major surgery within 4 weeks prior to start of study treatment.
Radiation therapy or brain radiotherapy ≤ 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed > 2 weeks prior to start of study treatment).
Impaired cardiac function or clinically significant cardio-vascular disease
Use of hematopoietic growth factors or transfusion support ≤ 2 weeks prior to start of study treatment.
Participant has conditions that are considered to have a high risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.
Serious non-healing wounds.
Pregnant or breast-feeding women
Women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as indicated
Pre-existing peripheral neuropathy > grade 1 (CTCAE v5.0)

Study Locations

United States
Highlands Oncology Group
Recruiting
Fayetteville, 72703 - Arkansas
Contact: London Hall (479-587-1700) - [email protected] - Joseph T. Beck
United States
UCLA Medical Center Santa Monica Location
Recruiting
Los Angeles, 90095 - California
Contact: Rachel Andes (310-582-4069) - [email protected] - Zev A. Wainberg
United States
Advent Health Cancer Institute
Recruiting
Orlando, 32804 - Florida
Contact: Michele Tisler (407-303-3235) - [email protected] - Mohamedtaki Tejani
United States
Fort Wayne Medical Oncology/Hematology, Inc. Jefferson Blvd
Recruiting
Fort Wayne, 46815 - Indiana
Contact: Brooke Long (317-436-0800) - [email protected] - Sunil Babu
United States
Ochsner Clinic and Hospital
Recruiting
New Orleans, 70121 - Louisiana
Contact: (504-842-4436) Lingling Du
United States
University of Missouri
Recruiting
Columbia, 65212 - Missouri
Contact: Brooke McDaniel (573-882-4979) - [email protected] - Puja Nistala
United States
NYU Clinical Cancer Center Dept of NYU Clin CancerCenter
Recruiting
New York, 10016 - New York
Contact: Nicole Gonias (212-731-5404) - [email protected] - Paul Oberstein
United States
NYU Clinical Cancer Center
Recruiting
New York, 10016 - New York
Contact: Lubin Zhu (212-731-5389) - [email protected] - Paul Oberstein
United States
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Can C
Recruiting
New York, 10021 - New York
Contact: (212-639-5070) Alice Zervoudakis
United States
Mount Sinai School of Medicine
Recruiting
New York, 10029 - New York
Contact: Shana Haynes-Harp (646-753-1922) - [email protected] - Deirdre Cohen
United States
Vanderbilt University Medical Center
Recruiting
Nashville, 37232 - Tennessee
Contact: Samantha Noel Stinson (+1 615 936 5795) - [email protected] - Dana Cardin
United States
US Oncology Research, Dallas
Recruiting
Dallas, 75204 - Texas
Contact: Stacy R Brice - stacy.b[email protected] - Scott Paulson
United States
Houston Methodist Hospital OPC 26
Recruiting
Houston, 77030 - Texas
Contact: Monica Rios (713-441-2215) - [email protected] - Maen Abdelrahim
United States
Huntsman Cancer Institute
Recruiting
Salt Lake City, 84112 - Utah
Contact: Susan Sharry (801-585-3453) - [email protected] - Heloisa Soares
United States
Seattle Cancer Care Alliance
Recruiting
Seattle, 98105 - Washington
Contact: Sean Park (+1 206 288 2056) - [email protected] - Elena Gabriela Chiorean
United States
Australia
Novartis Investigative Site
Recruiting
Adelaide, 5000
South Australia
Australia
Novartis Investigative Site
Recruiting
Perth,
Western Australia
Australia
Belgium
Novartis Investigative Site
Recruiting
Edegem, 2650
Antwerpen
Belgium
Novartis Investigative Site
Recruiting
Bonheiden, 2820
-
Belgium
Novartis Investigative Site
Recruiting
Bruxelles, 1000
-
Belgium
Novartis Investigative Site
Recruiting
Bruxelles, 1200
-
Belgium
Novartis Investigative Site
Recruiting
Leuven, 3000
-
Belgium
Brazil
Novartis Investigative Site
Recruiting
Brasilia, 70200-730
Distrito Federal
Brazil
Novartis Investigative Site
Recruiting
Porto Alegre, 90035-001
Rio Grande Do Sul
Brazil
Novartis Investigative Site
Recruiting
Ijuí, 98700-000
RS
Brazil
Novartis Investigative Site
Recruiting
Sao Paulo, 04014-002
SP
Brazil
Canada
Novartis Investigative Site
Recruiting
Brampton, L6R 3J7
Ontario
Canada
Novartis Investigative Site
Recruiting
Cambridge, N1R 3G2
Ontario
Canada
Novartis Investigative Site
Recruiting
Toronto, M4N 3M5
Ontario
Canada
China
Novartis Investigative Site
Recruiting
Xiamen, 361001
Fujian
China
Novartis Investigative Site
Recruiting
Harbin, 150081
Heilongjiang
China
Novartis Investigative Site
Recruiting
Nanjing, 210029
Jiangsu
China
Novartis Investigative Site
Recruiting
Dalian, 116001
Liaoning
China
Novartis Investigative Site
Recruiting
Jining, 272000
Shandong
China
Novartis Investigative Site
Recruiting
Shanghai, 200032
Shanghai
China
Novartis Investigative Site
Recruiting
Xian, 710061
Shanxi
China
Novartis Investigative Site
Recruiting
Tianjin, 300060
Tianjin
China
Novartis Investigative Site
Recruiting
Hangzhou, 310022
Zhejiang
China
Novartis Investigative Site
Recruiting
Beijing, 100021
-
China
Novartis Investigative Site
Recruiting
Beijing, 100036
-
China
Novartis Investigative Site
Recruiting
Beijing, 100730
-
China
Novartis Investigative Site
Recruiting
Guangzhou, 510000
-
China
Novartis Investigative Site
Recruiting
Shanghai, 200025
-
China
Novartis Investigative Site
Recruiting
Shanghai, 200433
-
China
Czech Republic
Novartis Investigative Site
Recruiting
Brno, 656 53
Czech Republic
Czech Republic
Novartis Investigative Site
Recruiting
Novy Jicin, 74101
Czech Republic
Czech Republic
Novartis Investigative Site
Recruiting
Hradec Kralove, 500 05
CZE
Czech Republic
Novartis Investigative Site
Recruiting
Praha 4, 140 59
-
Czech Republic
Finland
Novartis Investigative Site
Recruiting
Helsinki, 00290
-
Finland
Novartis Investigative Site
Recruiting
Tampere, FIN-33521
-
Finland
France
Novartis Investigative Site
Recruiting
Nice Cedex 2, 06189
Alpes Maritimes
France
Novartis Investigative Site
Recruiting
Besançon, 25030
Cedex
France
Novartis Investigative Site
Recruiting
Avignon Cedex, 84082
-
France
Novartis Investigative Site
Recruiting
Creteil, 94010
-
France
Novartis Investigative Site
Recruiting
Dijon, 21000
-
France
Novartis Investigative Site
Recruiting
Lyon Cedex 08, 69373
-
France
Novartis Investigative Site
Recruiting
Marseille, 13273
-
France
Novartis Investigative Site
Recruiting
Montpellier cedex 5, 34295
-
France
Novartis Investigative Site
Recruiting
Nantes Cedex 1, 44093
-
France
Novartis Investigative Site
Recruiting
Paris, 75015
-
France
Germany
Novartis Investigative Site
Recruiting
Berlin, 13353
-
Germany
Novartis Investigative Site
Recruiting
Bochum, 44791
-
Germany
Novartis Investigative Site
Recruiting
Essen, 45147
-
Germany
Novartis Investigative Site
Recruiting
Frankfurt, 60488
-
Germany
Novartis Investigative Site
Recruiting
Halle S, 06120
-
Germany
Novartis Investigative Site
Recruiting
Hamburg, 20249
-
Germany
Novartis Investigative Site
Recruiting
Ulm, 89081
-
Germany
Greece
Novartis Investigative Site
Recruiting
Thessaloniki, 540 07
-
Greece
Novartis Investigative Site
Recruiting
Thessaloniki, 57001
-
Greece
Hungary
Novartis Investigative Site
Recruiting
Budapest, 1062
-
Hungary
Novartis Investigative Site
Recruiting
Budapest, 1097
-
Hungary
Novartis Investigative Site
Recruiting
Budapest, H 1122
-
Hungary
Novartis Investigative Site
Recruiting
Debrecen, 4032
-
Hungary
Israel
Novartis Investigative Site
Recruiting
Jerusalem, 9112001
-
Israel
Novartis Investigative Site
Recruiting
Ramat Gan, 52621
-
Israel
Novartis Investigative Site
Recruiting
Tel Aviv, 6423906
-
Israel
Italy
Novartis Investigative Site
Recruiting
Firenze, 50134
FI
Italy
Novartis Investigative Site
Recruiting
Milano, 20133
MI
Italy
Novartis Investigative Site
Recruiting
Milano, 20162
MI
Italy
Novartis Investigative Site
Recruiting
Verona, 37126
VR
Italy
Japan
Novartis Investigative Site
Recruiting
Nagoya, 464 8681
Aichi
Japan
Novartis Investigative Site
Recruiting
Kashiwa, 277 8577
Chiba
Japan
Novartis Investigative Site
Recruiting
Yokohama-city, 241-8515
Kanagawa
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 541-8567
Osaka
Japan
Novartis Investigative Site
Recruiting
Chuo ku, 104 0045
Tokyo
Japan
Novartis Investigative Site
Recruiting
Koto ku, 135 8550
Tokyo
Japan
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 06591
Seocho Gu
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 03080
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 05505
-
Korea, Republic of
Netherlands
Novartis Investigative Site
Recruiting
Utrecht, 3543 AZ
-
Netherlands
Norway
Novartis Investigative Site
Recruiting
Nordbyhagen, 1478
Oslo
Norway
Novartis Investigative Site
Recruiting
Oslo, NO 0450
-
Norway
Singapore
Novartis Investigative Site
Recruiting
Singapore, 169610
-
Singapore
Slovakia
Novartis Investigative Site
Recruiting
Banska Bystrica, 975 17
-
Slovakia
Novartis Investigative Site
Recruiting
Bratislava, 83310
-
Slovakia
Novartis Investigative Site
Recruiting
Kosice, 041 91
-
Slovakia
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08035
Catalunya
Spain
Novartis Investigative Site
Recruiting
Hospitalet de LLobregat, 08907
Catalunya
Spain
Novartis Investigative Site
Recruiting
Santiago de Compostela, 15706
Galicia
Spain
Novartis Investigative Site
Recruiting
Madrid, 28009
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28034
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28040
-
Spain
Sweden
Novartis Investigative Site
Recruiting
Malmo, SE-205 02
-
Sweden
Novartis Investigative Site
Recruiting
Stockholm, 141 86
-
Sweden
Novartis Investigative Site
Recruiting
Umea, 901 85
-
Sweden
Switzerland
Novartis Investigative Site
Recruiting
Bellinzona, 6500
-
Switzerland
Novartis Investigative Site
Recruiting
Geneve 14, CH 1211
-
Switzerland
Novartis Investigative Site
Recruiting
St. Gallen, 9007
-
Switzerland
Taiwan
Novartis Investigative Site
Recruiting
Kuei Shan Chiang, 33305
Taoyuan Taiwan ROC
Taiwan
Novartis Investigative Site
Recruiting
Kaohsiung, 80756
-
Taiwan
Novartis Investigative Site
Recruiting
Taipei, 10002
-
Taiwan
Novartis Investigative Site
Recruiting
Taipei, 11217
-
Taiwan
Turkey
Novartis Investigative Site
Recruiting
Adana, 01250
-
Turkey
Novartis Investigative Site
Recruiting
Istanbul, 34722
-
Turkey
Novartis Investigative Site
Recruiting
Izmir, 35040
-
Turkey
Novartis Investigative Site
Recruiting
Sihhiye / Ankara, 06100
-
Turkey
United Kingdom
Novartis Investigative Site
Recruiting
Sutton, SM2 5PT
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Cambridge, CB2 2QQ
-
United Kingdom
Novartis Investigative Site
Recruiting
Liverpool, CH63 4JY
-
United Kingdom
Novartis Investigative Site
Recruiting
London, EC1A 7BE
-
United Kingdom
Novartis Investigative Site
Recruiting
Oxford, OX3 7LJ
-
United Kingdom

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]